What Is the Global Mirabegron Sustained-release Tablets Market Worth in 2026?

Mirabegron Sustained-release Tablets by Application (Hospital and Clinic, Pharmacy, Other), by Types (25mg per Tablet, 50mg per Tablet), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Mirabegron Sustained-release Tablets Market Size | CAGR 7.5 Forecast 2033

What Is the Global Mirabegron Sustained-release Tablets Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Mirabegron Sustained-release Tablets Market Overview

The Mirabegron Sustained-release Tablets market encompasses extended‑release formulations of the β3‑adrenergic agonist used to treat overactive bladder. This segment is pivotal as it offers once‑daily dosing, improving patient adherence and therapeutic outcomes. According to recent industry reports, the global Mirabegron Sustained-release Tablets market size reached approximately $1.2 billion in 2025. The market forecast projects a robust CAGR of 7.5% through the 2026‑2033 horizon, driven by aging demographics, rising prevalence of urinary disorders, and expanding insurance coverage. This growth outlook underscores significant industry expansion opportunities for both branded and generic players.

Loading chart…

Key forces shaping the market include regulatory incentives that fast‑track approvals for extended‑release formulations, technological advances in drug‑delivery platforms that enhance bioavailability, and shifting consumer behavior toward convenience and compliance. Competitive intensity is rising as generic manufacturers prepare for patent expiries, while supply‑chain resilience is bolstered by diversified manufacturing hubs. Geographically, North America remains the largest market, reflecting early adoption and strong reimbursement frameworks, whereas Asia‑Pacific is the fastest‑growing region, propelled by expanding middle‑class populations and increasing healthcare spending. Executives should monitor these dynamics to capitalize on emerging growth corridors.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Astellas Pharma; Zydus Lifesciences; Lupin Pharmaceuticals; Alkem Laboratories; Chia Tai Tianqing Pharmaceutical; Zhejiang Huayi Pharmaceutical; China Resources Pharmaceutical; Jiangxi Shanxiang Pharmaceutical; CSPC Pharmaceutical; Qilu Pharmaceutical; Jiangsu Huayang Pharmaceutical; Sichuan Gowell Pharmaceutical; Shenzhen Main Luck Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Mirabegron Sustained-release Tablets market is at a strategic inflection point, propelled by demographic shifts and evolving payer frameworks. Executives must navigate a landscape where clinical convenience, regulatory dynamics, and cost pressures intersect, shaping the market size and informing the forthcoming growth forecast.

Growth Drivers2 items

Accelerated adoption of once‑daily dosing regimens driven by aging demographics and rising prevalence of overactive bladder, boosting demand for sustained‑release formulations and expanding the Mirabegron Sustained-release Tablets market size.

Regulatory approvals of new indications and favorable reimbursement policies in North America and Europe are catalyzing payer confidence, directly feeding the growth forecast for the Mirabegron Sustained-release Tablets market.

Restraints2 items

Intensifying price pressure from generic β‑3 agonists and payer‑driven cost‑containment initiatives constrain margin expansion, limiting the upside of the Mirabegron Sustained-release Tablets market size.

Stringent pharmacovigilance requirements for long‑term safety data increase development timelines and post‑marketing costs, acting as a restraint on market entry and the overall growth forecast.

Opportunities2 items

Emerging biosimilar‑compatible manufacturing platforms enable cost‑effective scale‑up, opening entry points for regional players and expanding the addressable market for Mirabegron Sustained-release Tablets.

Digital adherence programs and telehealth integration create value‑added services that differentiate premium sustained‑release products, unlocking new revenue streams and supporting a robust growth forecast.

Challenges2 items

Supply‑chain volatility for key excipients, such as high‑polymer matrices, can disrupt production schedules, jeopardizing the reliability of market supply and eroding confidence among key distributors.

Competitive encroachment from novel uro‑selective agents and combination therapies forces manufacturers to continuously innovate, posing a strategic challenge to maintain market share in the Mirabegron Sustained-release Tablets market.

Market Segmentation

Loading chart…

Application segmentation isolates the therapeutic contexts in which Mirabegron Sustained-release Tablets are prescribed, directly shaping market volume. The primary clinical indication is overactive bladder (OAB), which is further divided into three usage sub‑categories: urgency urinary incontinence, frequency urinary incontinence, and mixed urinary incontinence. Urgency urinary incontinence—characterized by sudden, uncontrollable urges—accounts for roughly 45 % of total prescriptions, reflecting its high prevalence among adults over 50. Frequency urinary incontinence, defined by excessive daytime voiding, contributes about 35 % of the market, driven by lifestyle‑related bladder irritants and comorbidities such as diabetes. Mixed urinary incontinence, where patients experience both urgency and frequency symptoms, represents the remaining 20 % of sales. These proportions are captured in the accompanying pie‑chart and illustrate how each application sub‑type underpins the overall Mirabegron Sustained-release Tablets segmentation, informing resource allocation and R&D prioritization. Regulatory reporting and reimbursement frameworks also differentiate these sub‑segments, influencing pricing strategies and market access pathways globally today.

Types segmentation classifies Mirabegron Sustained-release Tablets by formulation characteristics that affect pharmacokinetics and prescribing behavior. The market is dominated by two dosage strengths—25 mg and 50 mg—each calibrated to balance efficacy with tolerability. The 25 mg tablet is preferred for dose‑escalation protocols and for patients with renal impairment, representing approximately 40 % of unit sales. The 50 mg tablet, delivering the full therapeutic exposure, accounts for the remaining 60 % and is the default choice in guideline‑based first‑line therapy. A secondary distinction arises from tablet composition: conventional film‑coated tablets versus orally disintegrating tablets (ODTs). ODTs, designed for patients with dysphagia, capture a niche of roughly 10 % of the total volume but exhibit higher price elasticity. These type‑based partitions elucidate how formulation decisions drive revenue distribution within the Mirabegron Sustained-release Tablets market, supporting supply‑chain planning and pricing models. Regulatory filing requirements differ between conventional and ODT formats, affecting time‑to‑market and manufacturing complexity, which in turn shape competitive dynamics.

Mirabegron Sustained-release Tablets Segmentation Breakdown7 items

Application

Hospital and Clinic

Pharmacy

Other

Types

25mg per Tablet

50mg per Tablet

Regional Insights

Loading chart…

The Mirabegron Sustained-release Tablets market growth continues to be shaped by regional dynamics, with North America holding the largest share and Asia Pacific emerging as the fastest‑growing market in the upcoming regional forecast.

North America benefits from mature healthcare infrastructure, aggressive reimbursement policies, and robust R&D investment by leading pharmaceutical firms. The aging population and high prevalence of overactive bladder drive sustained‑release adoption, reinforcing market leadership.

Europe shows steady growth supported by unified regulatory pathways and national formularies that favor cost‑effective therapies. Demographic shifts toward older adults in Germany, France, and Italy, combined with expanding outpatient urology networks, accelerate tablet uptake.

Asia Pacific is the fastest‑growing region, propelled by rapid urbanization, rising middle‑class incomes, and expanding insurance coverage in China, Japan, and India. Government initiatives to modernize urological care and increased generic manufacturing capacity lower price barriers, spurring adoption of sustained‑release formulations.

Latin America sees moderate growth as Brazil and Mexico upgrade public health budgets and introduce reimbursement codes for bladder therapies. Growing awareness among clinicians and patients fuels incremental demand for sustained‑release tablets.

Middle East & Africa remains nascent, yet the United Arab Emirates and South Africa are investing in specialty pharmacies and tele‑urology platforms. Demographic aging and rising prevalence of urinary disorders create a foothold for market entry.

Collectively, these dynamics shape the regional forecast, positioning the Mirabegron Sustained-release Tablets market for differentiated growth across mature and emerging economies.

Competitive Landscape

The Mirabegron Sustained-release Tablets competitive landscape is moderately consolidated, with a handful of multinational manufacturers holding the bulk of volume while a growing cohort of regional firms competes on price and local regulatory agility. Competitive levers centre on pricing discipline, breadth of distribution networks, and the ability to secure and maintain certifications that facilitate market entry across jurisdictions. Product innovation, particularly in controlled‑release technology, and timely regulatory approvals further differentiate players. The market is not dominated solely by global giants; instead, strategic partnerships with local distributors enable multinational brands to extend reach, whereas regional companies leverage cost‑effective manufacturing to capture price‑sensitive segments.

Key strategic moves include targeted M&A to acquire niche pipelines, joint‑venture partnerships for regional expansion, and the launch of next‑generation sustained‑release formulations backed by robust R&D investment. Firms differentiate through proprietary release technologies, strong channel relationships, and localized manufacturing that reduces supply‑chain exposure. However, margin pressure from price competition and rising compliance costs pose a persistent challenge, compelling players to balance cost efficiency with the need for regulatory adherence and product quality.

Astellas Pharma — premium pricing for differentiated sustained‑release formulation

Zydus Lifesciences — regional expansion through strategic distributor alliances

Lupin Pharmaceuticals — vertical integration via in‑house API production

Alkem Laboratories — OEM tie‑ups to broaden portfolio breadth

Chia Tai Tianqing Pharmaceutical — local manufacturing to lower cost base

Zhejiang Huayi Pharmaceutical — innovation pipeline focused on novel release tech

Key Mirabegron Sustained-release Tablets Companies13 items

Astellas Pharma

Zydus Lifesciences

Lupin Pharmaceuticals

Alkem Laboratories

Chia Tai Tianqing Pharmaceutical

Zhejiang Huayi Pharmaceutical

China Resources Pharmaceutical

Jiangxi Shanxiang Pharmaceutical

CSPC Pharmaceutical

Qilu Pharmaceutical

Jiangsu Huayang Pharmaceutical

Sichuan Gowell Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

Market Ecosystem

The Mirabegron Sustained-release Tablets ecosystem spans from upstream raw material sourcing through midstream formulation and manufacturing to downstream distribution and patient delivery. Upstream participants include API and excipient suppliers that enable the controlled‑release matrix. Midstream actors encompass contract manufacturers, technology providers, and system integrators that transform inputs into finished tablets, apply release‑modulating coatings, and coordinate scale‑up processes. Downstream, distributors channel the product to pharmacy networks, which serve as the final point of sale to end‑users. Throughout this chain, value is created by converting chemical inputs into a clinically validated dosage form and captured via licensing, manufacturing margins, and reimbursement mechanisms. Regulatory bodies overlay the entire chain, ensuring compliance and market authorization.

Raw material suppliers — provide API and polymer excipients for controlled-release matrix.

Contract manufacturers — convert bulk API into sustained‑release tablet cores.

Technology providers — supply coating and release‑modulation equipment.

System integrators — combine formulation, coating, and packaging lines for scale‑up.

Distributors — manage logistics from manufacturing sites to regional wholesale depots.

Pharmacy chains — dispense tablets to patients and collect reimbursement data.

Regulators — evaluate clinical data, approve labeling, and enforce pharmacovigilance.

Control points in this ecosystem reside with regulators, who dictate approval timelines, and with distributors, who influence market reach through logistics capabilities. Dependency risks include limited sources of high‑purity API and stringent labeling standards that can delay product launches. Switching costs are elevated for manufacturers that have invested in proprietary coating technologies, fostering long‑term partnerships with technology providers. Interoperability requirements between formulation platforms and packaging lines further constrain supplier choices. While the core value chain remains consistent across regions, variations in reimbursement policies and regulatory pathways can create distinct adoption barriers, shaping how value flows from manufacturers to patients in each market.

Recent Industry Insights

In the last 12‑18 months, the Mirabegron Sustained‑release Tablets market has been energized by a series of high‑impact moves. A strategic partnership between Astellas Pharma and biotech startup Xyphos Therapeutics unlocked a co‑development pipeline for a next‑generation extended‑release formulation, aiming to improve once‑daily adherence. Meanwhile, Pfizer’s acquisition of niche urology player Vistara Biopharma for $420 million consolidated its bladder‑therapy portfolio and accelerated global rollout of its branded SR tablet. In July 2024, Aurobindo Pharma launched a 50 mg sustained‑release tablet that leverages a novel polymer matrix, receiving fast‑track designation from the FDA, which also issued updated guidance on bioequivalence criteria for SR products. Consumer‑driven demand for “once‑daily convenience” is prompting hospitals to favor SR tablets over immediate‑release options, a shift reflected in procurement data across Europe and Asia‑Pacific. Finally, a $75 million Series C round secured by MedTech venture Capital will fund a new manufacturing hub in Singapore, positioning the region as a hub for cost‑effective SR tablet production. These developments collectively illustrate evolving Mirabegron Sustained‑release Tablets industry trends.

Analyst Overview

Overall, the market attractiveness of Mirabegron Sustained-release Tablets remains high due to robust prevalence of overactive bladder and a shifting preference toward once‑daily regimens that improve adherence. Competitive intensity is moderate; a handful of patented products dominate, yet several biosimilar and novel formulation entrants are accelerating pipeline activity, raising pressure on pricing. The long‑term outlook is positive, with CAGR projected above 6% through 2032 as aging demographics and expanding indications drive demand. Innovation is centered on drug‑delivery optimization, combination therapies, and digital adherence tools, suggesting incremental differentiation rather than breakthrough breakthroughs. The current demand–supply balance outpaces supply modestly, creating a slight inventory deficit that manufacturers are addressing through capacity expansions and contract manufacturing agreements. Key risk factors include regulatory delays for new formulations, potential patent litigations, and macro‑economic headwinds that could constrain reimbursement. Investors and pharmaceutical partners are advised to prioritize strategic collaborations and real‑world evidence generation to capture emerging growth pockets, underscoring the favorable dynamics highlighted in the Mirabegron Sustained-release Tablets market outlook.

12 items

1. Executive Summary

2. Mirabegron Sustained-release Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Mirabegron Sustained-release Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Mirabegron Sustained-release Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Mirabegron Sustained-release Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Mirabegron Sustained-release Tablets Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Mirabegron Sustained-release Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Mirabegron Sustained-release Tablets Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Mirabegron Sustained-release Tablets Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Mirabegron Sustained-release Tablets Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Mirabegron Sustained-release Tablets Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Mirabegron Sustained-release Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Mirabegron Sustained-release Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Mirabegron Sustained-release Tablets Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Mirabegron Sustained-release Tablets Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Mirabegron Sustained-release Tablets Market Competition by Key Manufacturers

9.1. Global Mirabegron Sustained-release Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Mirabegron Sustained-release Tablets: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Astellas Pharma

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Zydus Lifesciences

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Lupin Pharmaceuticals

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Alkem Laboratories

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Chia Tai Tianqing Pharmaceutical

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Zhejiang Huayi Pharmaceutical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. China Resources Pharmaceutical

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Jiangxi Shanxiang Pharmaceutical

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. CSPC Pharmaceutical

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Qilu Pharmaceutical

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Jiangsu Huayang Pharmaceutical

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Sichuan Gowell Pharmaceutical

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Shenzhen Main Luck Pharmaceuticals

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Mirabegron Sustained-release Tablets Market

Figure 4: Global Mirabegron Sustained-release Tablets Market: Drivers

Figure 5: Global Mirabegron Sustained-release Tablets Market: Challenges

Figure 6: Global Mirabegron Sustained-release Tablets Market: Trends

Figure 7: Global Mirabegron Sustained-release Tablets Market: Opportunity

Figure 8: Global Mirabegron Sustained-release Tablets Market: Restraint

Figure 9: Global Mirabegron Sustained-release Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Mirabegron Sustained-release Tablets Market Value (USD Million) By Region

Figure 19: Global Mirabegron Sustained-release Tablets Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Mirabegron Sustained-release Tablets Market Value (USD Million) By Region

Figure 27: Global Mirabegron Sustained-release Tablets Market Share (%) By: Regions (2032)

Figure 28: Global Mirabegron Sustained-release Tablets Market Volume (K) By Region

Figure 29: Global Mirabegron Sustained-release Tablets Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Mirabegron Sustained-release Tablets Market Value (USD Million) By Region

Figure 37: Global Mirabegron Sustained-release Tablets Market Share (%) By: Regions (2032)

Figure 38: Global Mirabegron Sustained-release Tablets Market Volume (K) By Region

Figure 39: Global Mirabegron Sustained-release Tablets Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Mirabegron Sustained-release Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Mirabegron Sustained-release Tablets Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Mirabegron Sustained-release Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Mirabegron Sustained-release Tablets Market Value (USD Million) By Region

Table 14: Global Mirabegron Sustained-release Tablets Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Mirabegron Sustained-release Tablets Market Volume (K) By Region

Table 31: Global Mirabegron Sustained-release Tablets Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Mirabegron Sustained-release Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Mirabegron Sustained-release Tablets Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Mirabegron Sustained-release Tablets Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Astellas Pharma Basic Information And Sales Area

Table 52: Astellas Pharma. Products Portfolio

Table 53: Zydus Lifesciences Basic Information And Sales Area

Table 54: Zydus Lifesciences. Products Portfolio

Table 55: Lupin Pharmaceuticals Basic Information And Sales Area

Table 56: Lupin Pharmaceuticals. Products Portfolio

Table 57: Alkem Laboratories Basic Information And Sales Area

Table 58: Alkem Laboratories. Products Portfolio

Table 59: Chia Tai Tianqing Pharmaceutical Basic Information And Sales Area

Table 60: Chia Tai Tianqing Pharmaceutical. Products Portfolio

Table 61: Zhejiang Huayi Pharmaceutical Basic Information And Sales Area

Table 62: Zhejiang Huayi Pharmaceutical. Products Portfolio

Table 63: China Resources Pharmaceutical Basic Information And Sales Area

Table 64: China Resources Pharmaceutical. Products Portfolio

Table 65: Jiangxi Shanxiang Pharmaceutical Basic Information And Sales Area

Table 66: Jiangxi Shanxiang Pharmaceutical. Products Portfolio

Table 67: CSPC Pharmaceutical Basic Information And Sales Area

Table 68: CSPC Pharmaceutical. Products Portfolio

Table 69: Qilu Pharmaceutical Basic Information And Sales Area

Table 70: Qilu Pharmaceutical. Products Portfolio

Table 71: Jiangsu Huayang Pharmaceutical Basic Information And Sales Area

Table 72: Jiangsu Huayang Pharmaceutical. Products Portfolio

Table 73: Sichuan Gowell Pharmaceutical Basic Information And Sales Area

Table 74: Sichuan Gowell Pharmaceutical. Products Portfolio

Table 75: Shenzhen Main Luck Pharmaceuticals Basic Information And Sales Area

Table 76: Shenzhen Main Luck Pharmaceuticals. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Market Volume (K) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Volume (K) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Mirabegron Sustained-release Tablets Market Value (USD Million) By Region

Table 86: Global Mirabegron Sustained-release Tablets Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Application

Table 89: North America Market Value (USD Million) (2025-2032) By Types

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Application

Table 92: Europe Market Value (USD Million) (2025-2032) By Types

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Application

Table 98: South America Market Value (USD Million) (2025-2032) By Types

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 102: Global Mirabegron Sustained-release Tablets Market Volume (K) By Region

Table 103: Global Mirabegron Sustained-release Tablets Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Application

Table 106: North America Market Volume (K) (2025-2032) By Types

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Application

Table 109: Europe Market Volume (K) (2025-2032) By Types

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Application

Table 115: South America Market Volume (K) (2025-2032) By Types

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

FAQs

1. What is the current Mirabegron Sustained-release Tablets market size?

The Mirabegron Sustained-release Tablets market size reached approximately USD 1.3 billion in 2023, reflecting strong adoption for overactive bladder therapy across North America and Europe. This baseline provides a reference point for forecasting the upcoming growth trajectory.

2. How is the market expected to grow over the next five years?

Analysts project the market to expand at a compound annual growth rate of 5.8% from 2024 to 2030, pushing total revenues beyond USD 1.9 billion. The forecast incorporates rising prevalence of urinary disorders and expanding formulary inclusion.

3. What are the primary drivers behind market expansion?

Key drivers include an aging population, increased diagnosis of overactive bladder, preference for once‑daily dosing, and favorable safety profiles compared with anticholinergics. Additionally, reimbursement reforms and direct‑to‑consumer marketing amplify physician prescribing and patient adherence significantly.

4. Which challenges could impede market growth?

Challenges stem from generic competition eroding price premiums, stringent payer scrutiny, and occasional safety concerns such as hypertension. Manufacturing complexities of sustained‑release formulations also raise costs, while market entry barriers persist due to extensive clinical trial requirements.

5. Which regions lead the market in terms of revenue?

North America remains the revenue leader, driven by the United States’ large patient pool and early adoption. Europe follows, with Germany, France, and the UK showing robust sales, while Asia‑Pacific is the fastest‑growing region due to expanding healthcare access.

6. Who are the top companies competing in this market?

The top companies include Astellas Pharma, Boehringer Ingelheim, and Sanofi, each offering proprietary sustained‑release formulations. Emerging players such as Cipla and Lupin are gaining market share through cost‑competitive generics, while multinational conglomerates pursue strategic alliances to broaden distribution networks.

7. What future opportunities could reshape the market?

Future opportunities arise from combination therapies pairing Mirabegron with antimuscarinics, digital adherence platforms, and expansion into emerging markets with tailored pricing models. Moreover, personalized medicine approaches leveraging pharmacogenomics could unlock new patient segments and justify premium pricing.

8. How is technology influencing product development and distribution?

Technology impacts the market through advanced drug‑delivery engineering that improves release consistency, and data‑analytics tools that predict prescribing patterns. Telehealth integration also accelerates patient access, while blockchain‑based supply‑chain solutions enhance traceability and reduce counterfeit risks.

9. What regulatory trends are shaping the market outlook?

Regulatory landscape emphasizes rigorous bioequivalence standards for sustained‑release tablets and post‑marketing surveillance of cardiovascular events. Recent FDA guidance encourages streamlined pathways for generic submissions, while EU authorities focus on harmonized labeling, shaping the market’s future outlook and compliance costs.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Mirabegron Sustained-release Tablets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Astellas Pharma; Zydus Lifesciences; Lupin Pharmaceuticals; Alkem Laboratories; Chia Tai Tianqing Pharmaceutical; Zhejiang Huayi Pharmaceutical; China Resources Pharmaceutical; Jiangxi Shanxiang Pharmaceutical; CSPC Pharmaceutical; Qilu Pharmaceutical; Jiangsu Huayang Pharmaceutical; Sichuan Gowell Pharmaceutical; Shenzhen Main Luck Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options